Genomic Health Inc (GHDX): Steven Shak , Chief Scientific Officer of Genomic Health Inc sold 10,000 shares on May 4, 2016. The Insider selling transaction was reported by the company on May 6, 2016 to the Securities and Exchange Commission. The shares were sold at $25.43 per share for a total value of $254,296.00 , the company said in a SEC Form 4 Filing.
Other Insider transactions have been reported by the company according to SEC Form 4, on Feb 11, 2016, James J Vaughn (Chief Commercial Officer) sold 3 shares at $28.00 per share price.On Jan 15, 2016, Randall S Livingston (director) sold 1,250 shares at $32.14 per share price.Also, On Jan 14, 2016, Kimberly J Popovits (President and CEO) sold 5,000 shares at $30.34 per share price.On Jan 14, 2016, G Bradley Cole (COO) sold 4,000 shares at $31.25 per share price.
Shares of Genomic Health (GHDX) ended Wednesday, May 4, 2016 session in red amid volatile trading. The shares closed down -1.33 points or -5.12% at $24.65 with 2,56,216 shares getting traded. Post opening the session at $25.78, the shares hit an intraday low of $24.54 and an intraday high of $25.95 and the price vacillated in this range throughout the day. The company has a market cap of $813 M and the number of outstanding shares has been calculated to be 3,29,80,932 shares. The 52-week high of Genomic Health is $35.79 and the 52-week low is $20.05.
Company has been under the radar of several Street Analysts.Genomic Health is Reiterated by Canaccord Genuity to Buy while Lowering the Price Target of the company shares to $ 38 from a previous price target of $44 . The Rating was issued on Feb 11, 2016.
Genomic Health Inc. is a healthcare company that provides actionable genomic information to personalize cancer treatment decisions. The Company offers its Oncotype DX tests as a clinical laboratory service where it analyzes the expression levels of genes in tumor tissue samples and provides physicians with a quantitative gene expression profile expressed as a single quantitative score which it calls a Recurrence Score for invasive breast cancer and colon cancer a DCIS Score for ductal carcinoma in situ (DCIS) and a Genomic Prostate Score (GPS) for prostate cancer. The Company’s Oncotype DX platform utilizes quantitative genomic analysis known as reverse transcription polymerase chain reaction (RT-PCR) in standard tumor pathology specimens to provide tumor-specific information or the oncotype of a tumor. Its offerings also include Oncotype DX Breast Cancer Test Oncotype DX Colon Cancer Test and Oncotype DX Prostate Cancer Test.